Allogene Therapeutics (ALLO) Baird 2024 Global Healthcare Conference summary

Company overview and financials

• Commercial-stage biotech focused on neuroscience and rare diseases, with two marketed products: NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome.

• 2024 net sales guidance: $600M for NUPLAZID, $340M–$370M for DAYBUE.

• Both products are first and only approved therapies for their indications; robust late- and early-stage pipeline in development.

• Cash flow positive, over $500M in cash, no debt, and ongoing business development focus.

NUPLAZID franchise and growth strategy

• Midlife cycle; focus on maximizing cash flow and profitability through top-line growth and expense management.

• Real-world evidence studies show mortality benefit and lower healthcare utilization versus off-label antipsychotics, driving franchise growth.

• Recent label clarification improved physician understanding; new patient starts and volume growth have increased.

• Disease awareness and direct-to-consumer campaigns launched to boost caregiver and patient engagement, with expected impact in the next 1–2 years.

• Approximately 130,000 U.S. patients with Parkinson's disease psychosis; about half of Parkinson's patients experience relevant symptoms.

Intellectual property and litigation

• Composition of matter, formulation, and method of use patents extend to 2030–2037; recent court ruling upheld key patents, with ongoing appeals and litigation.

• Confident in prevailing based on recent similar legal outcomes and strong patent position.